How have AVBP shares performed in 2024?

ArriVent BioPharma's stock was trading at $20.00 on January 1st, 2024. Since then, AVBP stock has increased by 5.1% and is now trading at $21.01. View the best growth stocks for 2024 here .

When did ArriVent BioPharma IPO?

(AVBP) raised $175 million in an initial public offering (IPO) on Friday, January 26th 2024. The company issued 9,722,222 shares at $18.00 per share.

When does the company's quiet period expire?

ArriVent BioPharma's quiet period expires on Wednesday, March 6th. ArriVent BioPharma had issued 9,722,222 shares in its public offering on January 26th. The total size of the offering was $174,999,996 based on an initial share price of $18.00. During the company's quiet period, insiders and underwriters involved in the IPO are prevented from issuing any research reports or earnings estimates for the company because of regulations issued by the Securities and Exchange Commission. Following the expiration of the company's quiet period, it's expected that the brokerages that served as underwriters on the stock will initiate research coverage on the company.

How do I buy shares of ArriVent BioPharma?

Shares of AVBP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:AVBP

ArriVent BioPharma (AVBP) Stock Price, News & Analysis

$21.01

-0.99 (-4.50%)

(As of 02/9/2024 08:55 PM ET)

Compare

Today's Range: $21.00
▼
$22.39
50-Day Range: N/A
52-Week Range: $19.40
▼
$25.95

Volume: 91,900 shs
Average Volume: 185,650 shs
Market Capitalization: $671.48 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis Chart Financials Insider Trades SEC Filings Social Media

Get ArriVent BioPharma alerts:

About ArriVent BioPharma Stock (NASDAQ:AVBP)

ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. It also engages in the development and commercialization of targeted cancer therapies for non-small-cell lung cancer (NSCLC) and other solid tumors. The company develops Furmonertinib, an epidermal growth factor receptor mutant-selective tyrosine kinase inhibitor that is in phase 3 clinical trial for the treatment of NSCLC patients; and ARR-002. It has strategic collaborations with Aarvik Therapeutics Inc. The company was incorporated in 2021 and is based in Newtown Square, Pennsylvania.

AVBP Stock Price History

30 days | 90 days | 365 days | Advanced Chart

AVBP Stock News Headlines

February 3, 2024 | americanbankingnews.com

ArriVent BioPharma, Inc. (NASDAQ:AVBP) Director Acquires $7,999,992.00 in Stock

February 2, 2024 | americanbankingnews.com

ArriVent BioPharma, Inc. (NASDAQ:AVBP) Major Shareholder Acquires $9,999,990.00 in Stock

See More Headlines

Receive AVBP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ArriVent BioPharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today: 2/12/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: N/A
Sub-Industry: N/A
Current Symbol: NASDAQ:AVBP
Previous Symbol: NASDAQ:AVBP
CUSIP: N/A
CIK: 1868279
Web: www.arrivent.com
Phone: 628-277-4836
Fax: N/A
Employees: 42
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: 31,960,000
Free Float: N/A
Market Cap: $671.48 million
Optionable: N/A
Beta: N/A

12 Stocks Corporate Insiders are Abandoning

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

Dr. Zhengbin Yao Ph.D. (Age 58)
Co-Founder, Chairman, President & CEO
Comp: $791.09k
Dr. Stuart Lutzker M.D. (Age 63)
Ph.D., Co-Founder, President of Research & Development and Director
Comp: $709.43k
Ms. Robin LaChapelle M.A. (Age 51)
Co-Founder & COO
Comp: $586.45k
Mr. Winston Kung M.B.A. (Age 48)
CFO & Treasurer
Ms. Yang Wang Ph.D.
Chief Technology Officer
Mr. James Paul Kastenmayer J.D. (Age 51)
Ph.D., General Counsel & Secretary
Dr. Dandan Dong (Age 39)
Chief Business Officer
Ms. Meghna Chowdary
Senior Vice President of Commercial Strategy

Key Competitors

View All Competitors

Insiders

View All Insider Transactions

AVBP Stock Analysis - Frequently Asked Questions

How have AVBP shares performed in 2024?: ArriVent BioPharma's stock was trading at $20.00 on January 1st, 2024. Since then, AVBP stock has increased by 5.1% and is now trading at $21.01.
View the best growth stocks for 2024 here.
When did ArriVent BioPharma IPO?: (AVBP) raised $175 million in an initial public offering (IPO) on Friday, January 26th 2024. The company issued 9,722,222 shares at $18.00 per share.
When does the company's quiet period expire?: ArriVent BioPharma's quiet period expires on Wednesday, March 6th. ArriVent BioPharma had issued 9,722,222 shares in its public offering on January 26th. The total size of the offering was $174,999,996 based on an initial share price of $18.00. During the company's quiet period, insiders and underwriters involved in the IPO are prevented from issuing any research reports or earnings estimates for the company because of regulations issued by the Securities and Exchange Commission. Following the expiration of the company's quiet period, it's expected that the brokerages that served as underwriters on the stock will initiate research coverage on the company.
How do I buy shares of ArriVent BioPharma?: Shares of AVBP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:AVBP) was last updated on 2/12/2024 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial